Bayer: phase III data confirms Gadavist gain
(CercleFinance.com) - Bayer's Gadavist showed high diagnostic accuracy for patients with coronary artery disease, according to data published in the Journal of the American College of Cardiology.
The two multinational, multicentre, non-randomised phase III studies looking at approximately 1,000 adults with suspected or known coronary artery disease further validated Gadavist's use in magnetic resonance as a non-invasive method, the German drugmaker said.
Gadavist was first approved in the US in 2011 for intravenous use in magnetic resonance imaging in adults and children to detect and visualise areas with disrupted blood brain barrier and abnormal vascularity of the central nervous system.
Coronary artery disease affects approximately 16.5 million Americans, Bayer said.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The two multinational, multicentre, non-randomised phase III studies looking at approximately 1,000 adults with suspected or known coronary artery disease further validated Gadavist's use in magnetic resonance as a non-invasive method, the German drugmaker said.
Gadavist was first approved in the US in 2011 for intravenous use in magnetic resonance imaging in adults and children to detect and visualise areas with disrupted blood brain barrier and abnormal vascularity of the central nervous system.
Coronary artery disease affects approximately 16.5 million Americans, Bayer said.
Copyright (c) 2020 CercleFinance.com. All rights reserved.